CellTrend diagnostic test
The CellTrend Diagnostic Test is a commercial ME/CFS diagnostic immunoassay created by CellTrend, a German biotechnology company, and Professor Doctor Carmen Scheibenbogen. Cell-Trend bases its test on the theory that a subset of 20-30% of all patients suffering from ME/CFS have developed elevated levels of three auto-antibodies, i.e., auto-antibodies against the b2-adrenergic receptor, auto-antibodies against the muscarinic cholinergic receptor 3 (M3) and auto-antibodies against the muscarinic cholinergic receptor 4 (M4). The CellTrend Diagnostic Test immunoassay is a biochemical test that measures the presence of these three auto-antibodies.
Notable studies[edit | edit source]
- 2016, Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome (Full Text)
Learn more[edit | edit source]
References[edit | edit source]
- Loebel, M; Grabowski, P; Heidecke, H; Bauer, S; Hanitsch, LG; Wittke, K; Meisel, C; Reinke, P; Volk, H; Fluge, Ø; Mella, O; Scheibenbogen, C (2016), "Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome", Brain, behavior, and immunity, 52: 32-39, doi:10.1016/j.bbi.2015.09.013